Prevention of thrombosis in heart valve diseases

Thromboembolism and bleeding during therapeutic anticoagulation are the major chronic risks for patients with native valvular heart disease and mechanical prosthetic heart valves. The recommendations for the prevention of thromboembolic events and bleeding complications are discussed. In particular, risk factors for thromboembolic events, indications and intensity of antithrombotic therapy, and approaches to practical problems of oral anticoagulation for patients with valvular heart disease are outlined.